 - Had disease progression while on a platinum containing regimen in the first-line setting or within 14 months after completing the first-line platinum regimen. Participants who received treatment with one immune checkpoint inhibitor regimen are eligible for example PD-1, PDL1, or CTLA4 and may have a longer interval since prior platinum-containing therapy 24 months. 